The long-term evaluation of pulmonary toxicity following isolated lung perfusion with melphalan in the rat

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 141-147

  Ueda, Kazuhiro ^a   Sugi, Kazuro ^a   Li, Tao Sheng ^a   Saeki, Kouichi ^a   Nawata, Sumihiko ^a   Esato, Kensuke ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Isolated lung perfusion; Long term; Melphalan; Rat; Toxicity

Indexed keywords

HETASTARCH; MELPHALAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FIBROSING ALVEOLITIS; ISOLATED LUNG; LUNG ALVEOLUS CELL; LUNG ALVEOLUS WALL; LUNG EDEMA; LUNG TOXICITY; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; LUNG; MALE; MELPHALAN; PERFUSION; RATS; RATS, INBRED F344;

EID: 0032897818     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Weksler B, Schneider A, Ng B. Burt M: Isolated single lung perfusion in the rat: an experimental model. J Appl Physiol 74: 2736-9, 1993.
2. Weksler B, Blumberg D, Lenert JT, Ng B, Fong Y, Burt ME: Isolated single-lung perfusion with TNF-a in a rat sarcoma lung metastasis model. Ann Thorac Surg 58: 328-32, 1994.
3. Nawata S, Abecasis N, Ross HM, Abolhoda A, Cheng H, Sachar KS, Burt ME: Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. J Thorac Cardiovasc Surg 112: 1542-8, 1996.
4. Weksler B, Lenert J, Ng B, Burt M: Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung metastases in a rat model. J Thorac Cardiovasc Surg 107: 50-54, 1994.
5. Abolhoda A, Brooks A, Nawata S, Kaneda Y, Cheng H, Burt ME: Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary. Ann Thorac Surg 64(1)1: 181-184, 1997.
6. Ng B, Lenert JT, Weksler B, Port JL, Ellis JL, Burt ME: Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung metastases in rats. Ann Thorac Surg 59(1): 205-209, 1995.
7. Port JT, Ng B, Ellis JL, Nawata S, Lenert JT, Burt ME: Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. Ann Thorac Surg 62(3): 848-852, 1996.
8. Ratto GB, Esposito M, Leprini A, Civalleri D, De Cian F, Vannozzi MO, Romano P, Canepa M, Zaccheo D: In situ lung perfusion with cisplatin. Cancer 71: 2962-70, 1993.
9. Baciewicz FA Jr, Arredondo M, Chaudhuri B, Crist KA, Basilius D, Bandyopadhyah S, Thomford NR, Chaudhuri PK: Pharmacokinetics and toxicity of isolated perfusion of lung with doxorubicin. J Surg Res 50: 124-128, 1991.
10. Minchin RF, Johnston MR, Schuller HM, Aiken MA, Boyd MR: Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer 61: 1320-1325, 1988.
11. Taetle R, Dickman PS, Feldman PS: Pulmonary histopathologic changes associated with melphalan therapy. Cancer 42: 1239-1245, 1978.
12. Westerfield BT, Michalski JP, McCombs C. Light RW: Reversible melphalan-induced lung damage. Am J Med 68: 767-771, 1980.
13. Cooper JA Jr, White DA, Matthay RA: Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 133: 321-340. 1986.
14. Wang HY, Port J, Hochwald SN, Burt ME: Revised technique of isolated lung perfusion in the rat. Ann Thorac Surg 60: 211-212, 1995.
15. Weksler B, Ng B, Lenert J, Burt M: A simplified method for endotracheal intubation in the rat. J Appl Physiol 76: 1823-1825. 1994.
16. Weksler B, Ng B, Lenert JT, Burt ME: Isolated single-lung perfusion: a study of the optimal perfusate and other pharmacokinetic factors. Ann Thorac Surg 60: 624-9, 1995.
17. Hasleton PS, Curry A: Anatomy of the lung. In: Hasleton PS, eds. Spencer's pathology of the lung (fifth edition). New York, McGraw-Hill Companies, 1996, pp1-44.
18. Hasleton PS: Lung injury due to radiation. In: Hasleton PS, eds. Spencer's pathology of the lung (fifth edition). New York, McGraw-Hill Companies, 1996, pp 537-549.